Patent licensing swap ends MoAb fight

Article

Monoclonal antibody competitorsNeoRx and Immunomedics have decided they have better things todo with their time and money than spend it in court. The two companiesannounced this month that they have settled a patent infringementbattle that began three

Monoclonal antibody competitorsNeoRx and Immunomedics have decided they have better things todo with their time and money than spend it in court. The two companiesannounced this month that they have settled a patent infringementbattle that began three years ago.

NeoRx of Seattle initiated the litigation in 1991 when it fileda lawsuit in U.S. District Court of New Jersey charging Immunomedicswith breach of contract and patent infringement of NeoRx patentson radionuclide labeling technologies (SCAN 4/20/94 and 9/11/91).Immunomedics, of Morris Plains, NJ, responded by filing a counterclaimagainst NeoRx.

In the settlement, the companies agreed to swap licenses topatents covering their respective technologies. Immunomedics willgive NeoRx a non-exclusive, royalty-free license to U.S. PatentNo. 4,331,647 for all of NeoRx's OncoTrac imaging agents. NeoRxwill give Immunomedics a non-exclusive, royalty-free license toU.S. Patent No. 4,877,868 for all of Immunomedics' imaging products.Neither company will receive or pay cash as part of the settlement.

Both companies are preparing for market launches of mono-clonalantibody-based imaging agents. NeoRx's OncoTrac kit for imagingsmall cell lung cancer is under review by the Food and Drug Administration.Immunomedics is steering its agent, ImmuRaid-CEA for imaging colorectalcancer, through the regulatory review process as well.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.